ethyl 3-hydroxy-1-phenyl-1H-pyrazole-4-carboxylate | 88585-10-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 3-hydroxy-1-phenyl-1H-pyrazole-4-carboxylate
• 英文别名: ethyl 3-oxo-1-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylate；ethyl 5-oxo-2-phenyl-1H-pyrazole-4-carboxylate
• CAS: 88585-10-8
• 化学式: C₁₂H₁₂N₂O₃
• 分子量: 232.239
• InChiKey: WLKZERYRSTXKEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 3-hydroxy-1-phenyl-1H-pyrazole-4-carboxylate 以 sodium hydroxide 为溶剂， 以96%的产率得到3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid
  参考文献：
  名称：

  .beta.-lactam antibacterial agents and compositions containing them

  摘要：

  式（1）的化合物或其药学上可接受的盐或体内水解酯： 其中，R1为苯基，取代苯基或含有最多三个氧、硫或氮的5-或6元杂环环，可选地取代羟基、氨基、卤素或C1-6烷氧基; X代表; 其中，RY为甲基或乙酰基; R2和R3可以相同也可以不同，每个都是氢、芳基、杂环基或可选地由芳基或杂环基取代的C1-6烷基; R4为氢、C1-6烷基羰基基、芳基、杂环基、可选地由芳基或杂环基取代的C1-6烷基; R5代表氢、甲氧基或-NHCHO; Y为: 其中，Y1为氧、硫或-CH2-，Z代表氢、卤素或有机基，例如C1-4烷氧基，-CH2Q或-CH=CH-Q，其中Q代表氢、卤素、羟基、巯基、氰基、羧基、羧酸酯、C1-4烷氧基、酰氧基、芳基、通过碳键结合的杂环基、杂环硫基或通过氮键结合的含氮杂环基。

  公开号：

  US04537886A1
• 作为产物：
  描述：

  乙氧基甲叉丙二酸二乙酯 、 1-乙酰基-2-苯基肼 在 三氯氧磷 作用下， 生成 ethyl 3-hydroxy-1-phenyl-1H-pyrazole-4-carboxylate
  参考文献：
  名称：

  3-和 5-Triflyloxy-1H-pyrazole-4-carboxylates 在 Pd 催化交叉偶联反应合成缩合吡唑中的作用

  摘要：

  容易获得的标题化合物 5-和 3-三氟甲氧基-1H-吡唑-4-羧酸乙酯（2 和 5）已用作与各种炔烃进行 Sonogashira 型交叉偶联反应的前体，以获得相应的 5- 和 3-炔基-4-（乙氧羰基）吡唑 3 和 6。后者邻位双官能合成子的环化提供了不同的稠合吡唑，例如吡喃并[4,3-c]吡唑-4(1H)-酮和-4(2H)-酮7和10以及1,5-二氢-和2,5-二氢-4H-吡唑并[4,3-c]吡啶-4-酮分别为9和12。三氟甲磺酸酯 2 与苯基硼酸的 Suzuki 偶联得到相应的 5-芳基吡唑。将 5-(3-氯苯基)-1-苯基-1H-吡唑-4-羧酸 (16) 与三氟甲磺酸一起加热导致意外的四环体系 18 的形成。

  DOI：

  10.1002/ejoc.201001560

文献信息

• [EN] 1,2-AZOLE DERIVATIVES WITH HYPOGLYSEMIC AND HYPOLIPIDEMIC ACTIVITY<br/>[FR] DERIVES 1,2-AZOLE PRESENTANT UNE ACTIVITE HYPOGLYCEMIQUE ET HYPOLIPIDEMIQUE
  申请人：TAKEDA CHEMICAL INDUSTRIES LTD

  公开号：WO2003099793A1

  公开（公告）日：2003-12-04

  A compound represented by the formula (1) wherein ring A is a ring optionally having 1 to 3 substituents; ring B is a 1,2-azole ring which may further have 1 to 3 substituents; Xa, Xb and Xc are the same or different and each is a bond, - O -, - S - and the like; Ya is a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; Yb and Yc are the same or different and each is a bond or a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; ring C is a monocyclic aromatic ring which may further have 1 to 3 substituents; and R represents -OR4 (R4 is hydrogen atom or optionally substituted hydrocarbon group) and the like, or a salt thereof or a prodrug thereof is useful as an agent for the prophylaxis or treatment of diabetes and the like.

  化合物的结构式（1），其中环A是一个环，可选地具有1到3个取代基；环B是一个1,2-唑环，可能进一步具有1到3个取代基；Xa、Xb和Xc相同或不同，每个都是键，-O-，-S-等；Ya是一个具有1到20个碳原子的二价脂肪烃残基；Yb和Yc相同或不同，每个是键或具有1到20个碳原子的二价脂肪烃残基；环C是一个可能进一步具有1到3个取代基的单环芳香环；R代表-OR4（R4是氢原子或可选择地取代的碳氢基团）等，或其盐或前药，可用作糖尿病的预防或治疗剂等。
• FIVE-MEMBERED HETEROCYCLIC COMPOUNDS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1541564A1

  公开（公告）日：2005-06-15

  The present invention provides a compound represented by the formula: wherein R1 is an optionally substituted 5-membered heterocyclic group; X, Y and V are the same or different and each is a bond, an oxygen atom, a sulfur atom and the like; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; ring A is an aromatic ring optionally further having 1 to 3 substituents; Z is -(CH2)n-Z1- or -Z1-(CH2)n- (n is an integer of 0 to 8, Z1 is a bond, an oxygen atom, a sulfur atom and the like); ring B is a nitrogen-containing heterocycle optionally further having 1 to 3 substituents; W is a bond or a divalent hydrocarbon group having 1 to 20 carbon atoms; R2 is a hydrogen atom, a cyano group, -PO(OR9)(OR10) (R9 and R10 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, and R9 and R10 are optionally bonded to form an optionally substituted ring) and the like, or a salt thereof, which has a superior adipose tissue weight decreasing action, a hypoglycemic action and a hypolipidemic action, and which is useful as an agent for the prophylaxis or treatment of obesity, diabetes mellitus, hyperlipidemia, impaired glucose tolerance, hypertension and the like.

  本发明提供了一种由以下式表示的化合物： 其中R1是可选择地取代的5-成员杂环基团；X、Y和V相同或不同，每个都是键，氧原子，硫原子等；Q是具有1到20个碳原子的二价碳氢基团；环A是一个芳香环，可选择地进一步具有1到3个取代基；Z是-(CH2)n-Z1-或-Z1-(CH2)n-（n是0到8的整数，Z1是键，氧原子，硫原子等）；环B是一个含氮杂环，可选择地进一步具有1到3个取代基；W是键或具有1到20个碳原子的二价碳氢基团；R2是氢原子，氰基，-PO(OR9)(OR10)（R9和R10相同或不同，每个是氢原子或可选择地取代的碳氢基团，R9和R10可选择地结合形成可选择地取代的环）等，或其盐，具有优越的减少脂肪组织重量的作用，降糖作用和降脂作用，并且作为预防或治疗肥胖症，糖尿病，高脂血症，糖耐量受损，高血压等的药剂是有用的。
• A direct preparation of 2-aryl-4-ethoxycarbonyl-3- pyrazolin-5-ones from aryl hydrazines
  作者：Andrew W. Taylor、Richard T. Cook

  DOI：10.1016/s0040-4020(01)89994-4

  日期：1987.1

  Aryl hydrazines (1) possessing an electron-withdrawing substituent on the phenyl ring, on treatment with diethyl (ethoxymethylene)malonate in ethanolic sodium ethoxide solution, have directly afforded 2-aryl-4-ethoxy-carbonyl-3-pyrazolin-5-ones (4). Spectroscopic evidence is presented to differentiate these compounds (4) from their 1-aryl isomers (3).

  在乙醇乙醇钠溶液中用（乙氧基亚甲基）丙二酸二乙酯处理后，在苯环上具有吸电子取代基的芳基肼（1）直接得到2-芳基-4-乙氧基-羰基-3-吡唑啉-5-酮（4）。光谱学证据表明，这些化合物（4）和其1-芳基异构体（3）有所区别。
• Five-membered heterocyclic alkanoic acid derivative
  申请人：——

  公开号：US20040063775A1

  公开（公告）日：2004-04-01

  The present invention relates to a compound represented by the formula 1 wherein R 1 is an optionally substituted 5-membered heterocyclic group; X is a bond etc.; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; Y is a bond etc.; ring A is an aromatic ring optionally further having 1 to 3 substituents; Z is —(CH 2 ) n —Z 1 — (n is an integer of 0 to 8 and Z 1 is a bond etc.) and the like; ring B is a 5-membered heterocycle optionally further having 1 to 3 substituents; W is a divalent saturated hydrocarbon group having 1 to 20 carbon atoms; R 2 is —OH etc., or a salt thereof. A pharmaceutical composition containing this compound is useful as a prophylactic or therapeutic agent of diseases such as diabetes mellitus and the like.

  本发明涉及一种由式1表示的化合物，其中R1是可选择取代的5元杂环基团; X是一个键等; Q是具有1到20个碳原子的双价碳氢基团; Y是一个键等; 环A是一个芳香环，可选择进一步具有1到3个取代基; Z是—(CH2)n—Z1—(n为0到8的整数，Z1是一个键等)等; 环B是一个可选择进一步具有1到3个取代基的5元杂环; W是具有1到20个碳原子的双价饱和碳氢基团; R2是—OH等，或其盐。包含该化合物的制药组合物可用作糖尿病等疾病的预防或治疗剂。
• Five-membered heterocyclic compounds
  申请人：Momose Yu

  公开号：US20060135578A1

  公开（公告）日：2006-06-22

  The present invention provides a compound represented by the formula: wherein R 1 is an optionally substituted 5-membered heterocyclic group; X, Y and V are the same or different and each is a bond, an oxygen atom, a sulfur atom and the like; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; ring A is an aromatic ring optionally further having 1 to 3 substituents; Z is —(CH 2 ) n -Z 1 - or -Z 1 -(CH 2 ) n — (n is an integer of 0 to 8, Z 1 is a bond, an oxygen atom, a sulfur atom and the like); ring B is a nitrogen-containing heterocycle optionally further having 1 to 3 substituents; W is a bond or a divalent hydrocarbon group having 1 to 20 carbon atoms; R 2 is a hydrogen atom, a cyano group, —PO(OR 9 )(OR 10 ) (R 9 and R 10 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, and R 9 and R 10 are optionally bonded to form an optionally substituted ring) and the like, or a salt thereof, which has a superior adipose tissue weight decreasing action, a hypoglycemic action and a hypolipidemic action, and which is useful as an agent for the prophylaxis or treatment of obesity, diabetes mellitus, hyperlipidemia, impaired glucose tolerance, hypertension and the like.

  本发明提供一种化合物，其化学式表示为：其中，R1为可选取的取代的5-成员杂环基；X、Y和V相同或不同，每个都是键，氧原子，硫原子等；Q为具有1到20个碳原子的二价碳氢基团；环A为芳香环，可选地进一步具有1到3个取代基；Z为—(CH2)n-Z1-或-Z1-(CH2)n—（n为0到8的整数，Z1为键，氧原子，硫原子等）；环B为含氮杂环，可选地进一步具有1到3个取代基；W为键或具有1到20个碳原子的二价碳氢基团；R2为氢原子，氰基，—PO(OR9)(OR10)（R9和R10相同或不同，每个都是氢原子或可选取的取代的碳氢基团，R9和R10可选择性地结合形成可选取的取代环）等，或其盐，具有优异的减轻脂肪组织重量、降血糖和降血脂作用，可用作预防或治疗肥胖症、糖尿病、高脂血症、糖耐量受损、高血压等的药剂。